NCT06552234 2026-04-13REPOROSCentre Hospitalier Intercommunal de Toulon La Seyne sur MerPhase 2 Recruiting30 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT05004116 2026-03-04A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerMemorial Sloan Kettering Cancer CenterPhase 1/2 Recruiting77 enrolled
NCT04094610 2025-11-19A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc.Phase 1/2 Recruiting75 enrolled